Find your perfect global partner for success.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

ABrain

As a next-generation leader in researching treatments for degenerative brain diseases, we are currently developing the world's first AAV gene therapy expressing a protein that treats degenerative brain diseases, focusing on patients suffering from Alzheimer's and Parkinson's diseases.

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma

Circle Pharma